Hill & Smith (HILS:LSE) Annual Reports & Investor Relations Material

Overview

Preclinical biotech Hillstream BioPharma is working on groundbreaking new therapies aimed at combating drug-resistant cancers, according to company officials. Hillstream's research focuses on ferroptosis, an anti-cancer mechanism that triggers iron-mediated cell death, as well as developing targeted immuno-oncology biologics. The company's lead product candidate is HSB-1216, an inducer of iron-mediated cell death designed to work against solid tumors. Hillstream is also developing HSB-3215, an anti-HER2 monoclonal antibody, and HSB-1940, a Quatrabody IO biologic that targets PD-1. Founded in 2017, Hillstream is headquartered in Bridgewater, New Jersey.

Annual Reports

Frequently Asked Questions

What is Hill & Smith's ticker?

Hill & Smith's ticker is HILS

What exchange is Hill & Smith traded on?

The company's shares trade on the LSE stock exchange

Where are Hill & Smith's headquarters?

They are based in Solihull, England

How many employees does Hill & Smith have?

There are 1001-5000 employees working at Hill & Smith

What is Hill & Smith's website?

It is hsgroup.com

What type of sector is Hill & Smith?

Hill & Smith is in the Industrial Goods sector

What type of industry is Hill & Smith?

Hill & Smith is in the General Contractors industry

Who are Hill & Smith's peers and competitors?

The following five companies are Hill & Smith's industry peers:

- Costain Group

- Galliford Try Holdings

- Macmahon

- Monadelphous Group Limited

- Hill & Smith